A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Multi-Gene, Polyvalent HIV-1 DNA Plasmid Prime/Env Protein Boost Vaccine Formulation, DP6-001 in Healthy Volunteers
Latest Information Update: 03 Nov 2021
At a glance
- Drugs DP 6001 (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions
- 02 Aug 2006 Status change
- 22 Nov 2005 New trial record.